Integra Lifesciences Holdings Corp
IART- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000917520
No open-market purchases or sales by Integra Lifesciences Holdings Corp insiders were filed in the last 90 days; 212 institutions reported holding it in 13F filings for Q2 2026, worth $1.32B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 24, 2026, 1:06 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $516.5M (31.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 25, 2025 | Feb 28, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Cost of revenue | $803.6M | $728.5M | $656.8M | $587.4M | $597.8M |
| Research and development | $99.0M | $115.4M | $104.2M | $101.2M | $93.1M |
| Selling, general and administrative | $699.7M | $717.0M | $656.6M | $616.3M | $637.4M |
| Operating income | -$493.4M | $28.4M | $111.5M | $238.9M | $197.2M |
| Interest expense | – | – | $51.4M | $49.6M | $50.4M |
| Income tax | -$47.0M | -$11.3M | $13.3M | $33.3M | $45.6M |
| Net income | -$516.5M | -$6.94M | $67.7M | $180.6M | $169.1M |
| EPS, basic | $-6.74 | $-0.09 | $0.85 | $2.18 | $2.00 |
| EPS, diluted | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 |
| Weighted shares, basic | 76.7M | 77.0M | 80.1M | 83.0M | 84.7M |
| Weighted shares, diluted | 76.7M | 77.0M | 80.3M | 83.5M | 85.5M |
| Margins and growth | |||||
| Operating margin | -30.2% | 1.8% | 7.2% | 15.3% | 12.8% |
| Net margin | -31.6% | -0.4% | 4.4% | 11.6% | 11.0% |
| Revenue growth, year over year | +1.5% | +4.5% | −1.0% | +1.0% | +12.4% |
| Net income growth, year over year | – | −110.3% | −62.5% | +6.8% | +26.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 25, 2025 | Feb 28, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Cash and equivalents | $235.0M | $246.4M | $276.4M | $456.7M | $513.4M |
| Short-term investments | $28.7M | $27.2M | $32.7M | – | – |
| Accounts receivable | $278.8M | $272.4M | $259.3M | $263.5M | $231.8M |
| Inventory | $492.7M | $429.1M | $389.6M | $324.6M | $317.4M |
| Total current assets | $1.16B | $1.08B | $1.06B | $1.16B | $1.15B |
| Property, plant and equipment | $444.3M | $405.7M | $340.2M | $311.3M | $311.7M |
| Goodwill | $615.2M | $1.10B | $1.06B | $1.04B | $1.01B |
| Intangible assets | $1.13B | $1.21B | $1.07B | $1.13B | $1.15B |
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | $3.78B |
| Total current liabilities | $456.0M | $922.1M | $307.0M | $320.9M | $340.0M |
| Long-term debt | $726.6M | $760.5M | $775.0M | $775.0M | $843.8M |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | $2.10B |
| Shareholders' equity | $1.04B | $1.55B | $1.59B | $1.80B | $1.68B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 25, 2025 | Feb 28, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Operating cash flow | $50.4M | $129.4M | $140.0M | $264.5M | $312.4M |
| Capital expenditures | $81.4M | $104.4M | $66.9M | $42.3M | $48.0M |
| Free cash flow | -$31.1M | $25.0M | $73.1M | $222.1M | $264.4M |
| Stock-based compensation | $18.6M | $24.4M | $20.1M | $27.7M | $36.2M |
| Share buybacks | $221.0K | $52.5M | $275.0M | $125.0M | $0 |
| Investing cash flow | -$108.1M | -$390.8M | -$94.2M | -$58.6M | -$161.4M |
| Financing cash flow | $28.3M | $237.9M | -$229.9M | -$252.0M | -$98.2M |
| Net change in cash | -$11.3M | -$30.0M | -$180.3M | -$56.8M | $43.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.1% | 1.5% | 1.3% | 1.8% | 2.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 77.8M | −0.1% | SEC |
| Jul 28, 2026 | 77.8M | −0.2% | SEC |
| May 4, 2026 | 77.8M | +0.1% | SEC |
| Feb 25, 2026 | 77.9M | +0.9% | SEC |
| Oct 29, 2025 | 77.9M | +0.9% | SEC |
| Jul 30, 2025 | 77.9M | +0.4% | SEC |
| May 2, 2025 | 77.7M | −1.4% | SEC |
| Feb 24, 2025 | 77.2M | −1.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.